The Rosen Law Firm was sole Lead Counsel in this class action in the U.S. District Court of the Central District of California. The complaint alleged violations of §§10b and 20(a) of the Securities Exchange Act arising out of the issuance of false statements concerning the Company’s clinical trial involving its principal product. The parties agreed to settle this action for $2.5 million in cash.
